SYBX Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Synlogic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.41 |
| 52 Week High | US$5.12 |
| 52 Week Low | US$1.22 |
| Beta | 0.84 |
| 11 Month Change | -1.75% |
| 3 Month Change | -6.33% |
| 1 Year Change | -32.78% |
| 33 Year Change | -96.45% |
| 5 Year Change | -95.52% |
| Change since IPO | -99.22% |
Recent News & Updates
Recent updates
Companies Like Synlogic (NASDAQ:SYBX) Could Be Quite Risky
Dec 28
Can Synlogic (NASDAQ:SYBX) Afford To Invest In Growth?
Sep 12We're A Little Worried About Synlogic's (NASDAQ:SYBX) Cash Burn Rate
May 01Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation
Nov 23Synlogic Therapeutics: SYNB1934 Advances To Phase 3
Oct 20Synlogic gets milestone payment under Roche pact to discover synthetic biotic for bowel disease
Sep 06Synlogic's metabolic disorder drug gets FDA fast track status
Aug 23Synlogic Q2 2022 Earnings Preview
Aug 10Is Synlogic (NASDAQ:SYBX) In A Good Position To Invest In Growth?
Aug 09Synlogic begins dosing in early-stage trial of SYNB1353 for rare metabolic disorder
Jul 12Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation
Jan 11Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth
Sep 28Synlogic (SYBX) Investor Presentation - Slideshow
Jun 08Here's Why We Think Synlogic, Inc.'s (NASDAQ:SYBX) CEO Compensation Looks Fair
Jun 03Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth
Feb 23Synlogic (NASDAQ:SYBX) Share Prices Have Dropped 67% In The Last Three Years
Jan 19Synlogic outlines clinical milestones for 2021
Jan 11Our Take On Synlogic's (NASDAQ:SYBX) CEO Salary
Dec 15
Synlogic, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Synlogic EPS beats by $0.10
Nov 05Shareholder Returns
| SYBX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.1% | -3.7% | 0.3% |
| 1Y | -32.8% | 15.2% | 31.1% |
Return vs Industry: SYBX underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: SYBX underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| SYBX volatility | |
|---|---|
| SYBX Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SYBX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SYBX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 6 | Tony Awad | www.synlogictx.com |
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
Synlogic, Inc. Fundamentals Summary
| SYBX fundamental statistics | |
|---|---|
| Market cap | US$16.90m |
| Earnings (TTM) | -US$37.18m |
| Revenue (TTM) | US$2.78m |
5.9x
P/S Ratio-0.4x
P/E RatioIs SYBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYBX income statement (TTM) | |
|---|---|
| Revenue | US$2.78m |
| Cost of Revenue | US$0 |
| Gross Profit | US$2.78m |
| Other Expenses | US$39.96m |
| Earnings | -US$37.18m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.18 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,338.82% |
| Debt/Equity Ratio | 0% |
How did SYBX perform over the long term?
See historical performance and comparison